Serum peptide profiles of Duchenne Muscular Dystrophy (DMD) patients evaluated by data handling strategies for high resolution content

Journal of Proteomics and Bioinformatics

Volumn 5, Issue 4, 2012, Pages 96-103

  Nadarajah, Vishna D ^a   Mertens, Bart J A ^a   Dalebout, Hans ^a   Bladergroen, Marco R ^a   Alagaratnam, Sharmini ^a   Garrood, Penny ^b   Bushby, Kate ^b   Straub, Volker ^b   Deelder, André M ^a   den Dunnen, Johan T ^a   van Ommen, Gert Jan B ^a   T'Hoen, Peter A C ^a   van der Burgt, Yuri E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Data handling; Duchenne Muscular Dystrophy; High resolution; Mass spectrometry; Serum peptide profiles

Indexed keywords

PEPTIDE;

ANALYTICAL ERROR; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATIENT ASSESSMENT; PEPTIDE ANALYSIS; PRESCHOOL CHILD; REVERSED PHASE LIQUID CHROMATOGRAPHY; SCHOOL CHILD; SOLID PHASE EXTRACTION; VALIDATION STUDY;

EID: 84860897149     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.1000219     Document Type: Article

References (32)

1. Barbarini N, Magni P (2010) Accurate peak list extraction from proteomic mass spectra for identification and profiling studies. BMC Bioinformatics 11: 518.
2. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422: 198-207.
3. Diamandis EP (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3: 367-378.
4. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
5. Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, et al. (2011) On the development of plasma protein biomarkers. J Proteome Res 10: 5-16.
6. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, et al. (2004) Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76: 1560-1570.
7. Callesen AK, Madsen JS, Vach W, Kruse TA, Mogensen O, et al. (2009) Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics 9: 1428-1441.
8. Nicolardi S, Palmblad M, Hensbergen PJ, Tollenaar RA, Deelder AM, et al. (2011) Precision profiling and identification of human serum peptides using Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 25: 3457-3463.
9. Nicolardi S, Palmblad M, Dalebout H, Bladergroen M, Tollenaar RA, et al. (2010) Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling. J Am Soc Mass Spectrom 21: 1515-1525.
10. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, et al. (2004) Highresolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 11: 163-178.
11. Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, et al. (2005) Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 5: 4107-4117.
12. Morris JS, Coombes KR, Koomen J, Baggerly KA, Kobayashi R (2005) Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics 21: 1764-1775.
13. Du P, Kibbe WA, Lin SM (2006) Improved peak detection in mass spectrum by incorporating continuous wavelet transform-based pattern matching. Bioinformatics 22: 2059-2065.
14. He S, Li X, Viant MR, Yao X (2009) Profiling MS proteomics data using smoothed non-linear energy operator and Bayesian additive regression trees. Proteomics 9: 4176-4191.
15. Mertens BJA, van der Burgt YEM, Velstra B, Mesker WE, Tollenaar RAEM, et al. (2011) On the use of double cross-validation for the combination of proteomic mass spectral data for enhanced diagnosis and prediction. Stat Probab Lett 81: 759-766.
16. Noy K, Fasulo D (2007) Improved model-based, platform-independent feature extraction for mass spectrometry. Bioinformatics 23: 2528-2535.
17. Rompp A, Dekker L, Taban I, Jenster G, Boogerd W, et al. (2007) Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. Proteomics 7: 474-481.
18. Hilario M, Kalousis A, Pellegrini C, Muller M (2006) Processing and classification of protein mass spectra. Mass Spectrom Rev 25: 409-449.
19. Bushby K, Lochmuller H, Lynn S, Straub V (2009) Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 374: 1849-1856.
20. Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, et al. (2011) Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 21: 569-578.
21. Pietrowska M, Marczak L, Polanska J, Behrendt K, Nowicka E, et al. (2009) Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Transl Med 7: 60.
22. Garrood P, Hollingsworth KG, Eagle M, Aribisala BS, Birchall D, et al. (2009) MR imaging in Duchenne muscular dystrophy: quantification of T1-weighted signal, contrast uptake, and the effects of exercise. J Magn Reson Imaging 30: 1130-1138.
23. Alagaratnam S, Mertens BJ, Dalebout JC, Deelder AM, van Ommen GJ, et al. (2008) Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics 8: 1552-1563.
24. Gianazza E, Mainini V, Castoldi G, Chinello C, Zerbini G, et al. (2010) Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy. J Proteomics 73: 593-601.
25. Hortin GL (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52: 1223-1237.
26. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, et al. (2010) A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 10: 3388-3392.
27. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284.
28. Liangpunsakul S, Lai X, Ringham HN, Crabb DW, Witzmann FA (2009) Serum Proteomic Profiles In Subjects with Heavy Alcohol Abuse. J Proteomics Bioinform 2: 236-243.
29. Saito T, Yamamoto Y, Matsumura T, Fujimura H, Shinno S (2009) Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophy. Brain Dev 31: 612-617.
30. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, et al. (2008) Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22: 1747-1752.
31. Jacquemin B, Antoniades C, Nyberg F, Plana E, Mueller M, et al. (2008) Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 52: 941-952.
32. Righetti PG, Boschetti E (2008) The Proteo Miner and the Forty Niners: searching for gold nuggets in the proteomic arena. Mass Spectrom Rev 27: 596-608.